Showing results (1-10 of 138) with videos related to
Sort By:
Pageof 14
Diabetologia|July 11, 2023
Socioeconomic aspects of incretin-based therapyThomas Karagiannis, Eleni Bekiari, Apostolos TsapasTherapeutic Advances in Drug Safety|August 2, 2014
Safety of dipeptidyl peptidase 4 inhibitors: a perspective reviewThomas Karagiannis, Panagiota Boura, Apostolos TsapasAnnals of Internal Medicine|January 1, 2024
In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wkAris Liakos, Thomas Karagiannis, Apostolos TsapasAnnals of Internal Medicine|December 14, 2020
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitorsAris Liakos, Apostolos Tsapas, Eleni BekiariCurrent Vascular Pharmacology|September 29, 2012
Non-dipping status in arterial hypertension: an overviewMaria Sarigianni, Konstantinos Dimitrakopoulos, Apostolos TsapasAnnals of Internal Medicine|May 4, 2026
In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 yThomas Karagiannis, Ioannis Avgerinos, Apostolos Tsapas, et al.Core Evidence|March 30, 2017
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapyThomas Karagiannis, Eleni Bekiari, Apostolos TsapasAnnals of Internal Medicine|March 1, 2021
KDIGO made 12 recommendations for managing diabetes with CKDThomas Karagiannis, Apostolos Tsapas, Eleni BekiariAnnals of Internal Medicine|July 21, 2020
Some glucose-lowering drugs reduce risk for major adverse cardiac eventsAris Liakos, Apostolos Tsapas, Eleni BekiariDiabetes Research and Clinical Practice|November 9, 2022
Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysisAthina Stamati, Thomas Karagiannis, Apostolos Tsapas, et al.Pageof 14